EATG » AbbVie submits to FDA its investigational pan-genotypic regimen of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C

AbbVie submits to FDA its investigational pan-genotypic regimen of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C

If approved, glecaprevir/pibrentasvir will provide an eight week once-daily, ribavirin-free treatment option for HCV patients without cirrhosis across all major genotypes

AbbVie’s investigational regimen was granted Breakthrough Therapy Designation by the FDA for genotype 1 patients not cured with prior direct-acting antivirals

AbbVie is on track to submit a Marketing Authorization Application for glecaprevir/pibrentasvir in the European Union in early 2017

To read the press release, click here.

Source:
AbbVie
News categories: Hepatitis, EMA/FDA